Inhibitor Therapeutics annual return on equity
2015
2016
2017
2018
2022
2023
2024
2025
Inhibitor Therapeutics Return on Equity (ROE) Growth & History (INTI)
Inhibitor Therapeutics's return on equity was −952.30% for fiscal 2025.
View full Inhibitor Therapeutics company overviewInhibitor Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −952.30% | −860.43 pp |
| 2024 | 2024-12-31 | −91.87% | −47.31 pp |
| 2023 | 2023-12-31 | −44.57% | −562.43 pp |
| 2022 | 2022-12-31 | 517.86% | — |
| 2018 | 2018-12-31 | −4,575.07% | −4433.31 pp |
| 2017 | 2017-12-31 | −141.77% | +46.06 pp |
| 2016 | 2016-12-31 | −187.83% | +1437.32 pp |
| 2015 | 2015-12-31 | −1,625.15% | — |
Inhibitor Therapeutics quarterly return on equity
Q4.14
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −198.08% | −178.70 pp |
| Q2 2025 | 2025-06-30 | −63.83% | −52.40 pp |
| Q1 2025 | 2025-03-31 | −37.93% | −24.13 pp |
| Q4 2024 | 2024-12-31 | −52.74% | −32.85 pp |
| Q3 2024 | 2024-09-30 | −19.38% | −9.58 pp |
| Q2 2024 | 2024-06-30 | −11.43% | −2.63 pp |
| Q1 2024 | 2024-03-31 | −13.80% | −7.08 pp |
| Q4 2023 | 2023-12-31 | −19.89% | −598.60 pp |
| Q3 2023 | 2023-09-30 | −9.80% | — |
| Q2 2023 | 2023-06-30 | −8.80% | — |
| Q1 2023 | 2023-03-31 | −6.72% | — |
| Q4 2022 | 2022-12-31 | 578.71% | — |
| Q4 2017 | 2017-12-31 | −147.83% | −95.03 pp |
| Q3 2017 | 2017-09-30 | −48.88% | −4.02 pp |
| Q2 2017 | 2017-06-30 | −34.94% | +31.94 pp |
| Q1 2017 | 2017-03-31 | −59.55% | +2301.31 pp |
| Q4 2016 | 2016-12-31 | −52.80% | +91.35 pp |
| Q3 2016 | 2016-09-30 | −44.86% | +41.41 pp |
| Q2 2016 | 2016-06-30 | −66.88% | +51.61 pp |
| Q1 2016 | 2016-03-31 | −2,360.86% | — |
| Q4 2015 | 2015-12-31 | −144.15% | +3274.64 pp |
| Q3 2015 | 2015-09-30 | −86.27% | — |
| Q2 2015 | 2015-06-30 | −118.49% | — |
| Q4 2014 | 2014-12-31 | −3,418.79% | — |
Inhibitor Therapeutics return on equity trends
Between the periods ended 2015-12-31 and 2025-12-31, Inhibitor Therapeutics's return on equity increased from −1,625.15% to −952.30%, a change of +672.85 percentage points. The latest reported quarter, Q3 2025, shows −198.08%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibitor Therapeutics source filings ↗